{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:19:26Z","timestamp":1785403166014,"version":"3.56.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102406"],"award-info":[{"award-number":["82102406"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cmi.2026.04.004","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:32:41Z","timestamp":1776011561000},"page":"1352-1359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rifapentine dosing for drug-susceptible tuberculosis: stage 1 of a seamless phase 2\/3 randomized clinical trial"],"prefix":"10.1016","volume":"32","author":[{"given":"Yang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbo","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.04.004_bib1","series-title":"Global tuberculosis report 2025","year":"2025"},{"key":"10.1016\/j.cmi.2026.04.004_bib2","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.04.004_bib3","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","article-title":"A four-month gatifloxacin-containing regimen for treating tuberculosis","volume":"371","author":"Merle","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.04.004_bib4","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cmi.2026.04.004_bib5","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2104535","article-title":"Shorter treatment for nonsevere tuberculosis in African and Indian children","volume":"386","author":"Turkova","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.04.004_bib6","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cmi.2026.04.004_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","article-title":"Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: An official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"211","author":"Saukkonen","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2026.04.004_bib8","series-title":"WHO consolidated guidelines on tuberculosis: Module 4: Treatment and care","year":"2025"},{"key":"10.1016\/j.cmi.2026.04.004_bib9","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1164\/rccm.202501-0222LE","article-title":"The 4-Month HPMZ treatment regimen for drug-susceptible pulmonary tuberculosis - A Word of caution","volume":"211","author":"Wilson","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2026.04.004_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae178","article-title":"Experience with four-month rifapentine and moxifloxacin-based tuberculosis treatment in San Francisco","volume":"11","author":"Louie","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2026.04.004_bib11","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12879-023-08264-2","article-title":"Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: Study protocol of a multicenter randomized controlled trial","volume":"23","author":"Feng","year":"2023","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2026.04.004_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-097912","article-title":"Comparative efficacy and safety of high-dose rifamycin regimens for tuberculosis treatment: A Bayesian network meta-analysis","volume":"15","author":"Feng","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2026.04.004_bib13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.5588\/ijtld.23.0494","article-title":"Conjugated hyperbilirubinemia associated with accidental rifapentine overdose","volume":"28","author":"Yohane","year":"2024","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.cmi.2026.04.004_bib14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5588\/ijtld.24.0616","article-title":"Challenges to initiate and complete a 4-month rifapentine-moxifloxacin TB treatment regimen","volume":"29","author":"Galvis","year":"2025","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.cmi.2026.04.004_bib15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1164\/rccm.201410-1843OC","article-title":"Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial","volume":"191","author":"Dorman","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2026.04.004_bib16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijid.2019.03.036","article-title":"Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study","volume":"83","author":"Akkerman","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2026.04.004_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107230","article-title":"Assessing hepatotoxicity in novel and standard short regimens for rifampicin-resistant tuberculosis: Insights from the TB-TRUST and TB-TRUST-plus trials","volume":"148","author":"Song","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2026.04.004_bib18","series-title":"Guidance on evidence generation on new regimens for tuberculosis treatment","year":"2024"},{"key":"10.1016\/j.cmi.2026.04.004_bib19","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1093\/cid\/ciaf351","article-title":"A short, all-oral regimen for pre-extensively drug-resistant tuberculosis: A multicenter open-label single-arm study","volume":"81","author":"Li","year":"2026","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.04.004_bib20","article-title":"People first: A participatory community approach on patient-reported outcomes in tuberculosis","volume":"20","author":"Mart\u00edn","year":"2024","journal-title":"Breathe (Sheff)"},{"key":"10.1016\/j.cmi.2026.04.004_bib21","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/S1473-3099(24)00597-8","article-title":"Representativeness and adverse event reporting in late-phase clinical trials for rifampin-susceptible tuberculosis: A systematic review","volume":"25","author":"Burman","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.04.004_bib22","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMoa2212537","article-title":"Treatment strategy for rifampin-susceptible tuberculosis","volume":"388","author":"Paton","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cmi.2026.04.004_bib23","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2214-109X(22)00498-3","article-title":"Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): A within-trial analysis of a randomised controlled trial","volume":"11","author":"Rosu","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.cmi.2026.04.004_bib24","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/clpt.2011.323","article-title":"Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers","volume":"91","author":"Dooley","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2026.04.004_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cpt.634","article-title":"Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials","volume":"102","author":"Savic","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2026.04.004_bib26","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1164\/rccm.201912-2489OC","article-title":"Rifapentine population pharmacokinetics and dosing recommendations for latent tuberculosis infection","volume":"202","author":"Hibma","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2026.04.004_bib27","doi-asserted-by":"crossref","first-page":"9400","DOI":"10.1038\/s41467-024-53273-7","article-title":"Risk-stratified treatment for drug-susceptible pulmonary tuberculosis","volume":"15","author":"Chang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2026.04.004_bib28","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","article-title":"A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis","volume":"24","author":"Imperial","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2026.04.004_bib29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cmi.2025.10.027","article-title":"Acquired resistance during short-course treatment for rifampicin-resistant tuberculosis","volume":"32","author":"Chen","year":"2026","journal-title":"Clin Microbiol Infect"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26001874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26001874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:22:22Z","timestamp":1784550142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26001874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1198743X26001874"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.04.004","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rifapentine dosing for drug-susceptible tuberculosis: stage 1 of a seamless phase 2\/3 randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}